Protonitazepyne

Last updated

Protonitazepyne
Protonitazepyne structure.png
Identifiers
  • 5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazole
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C23H28N4O3
Molar mass 408.502 g·mol−1
3D model (JSmol)
  • CCCOC1=CC=C(C=C1)CC2=NC3=C(N2CCN4CCCC4)C=CC(=C3)[N+](=O)[O-]
  • InChI=1S/C23H28N4O3/c1-2-15-30-20-8-5-18(6-9-20)16-23-24-21-17-19(27(28)29)7-10-22(21)26(23)14-13-25-11-3-4-12-25/h5-10,17H,2-4,11-16H2,1H3
  • Key:KCRWXNIIXGBPID-UHFFFAOYSA-N

Protonitazepyne (N-pyrrolidino protonitazene) is a benzimidazole derivative with opioid effects, which has been sold as a designer drug over the internet, first being mentioned in mid 2022 and definitively identified in drug seizures in Canada in early 2023 and Ireland in late 2023. [1] It has since been identified by CanTEST in May 2024 in Australia. [2] It is an analogue of protonitazene where the N,N-diethyl group has been substituted for pyrrolidine group. While formal studies into its pharmacology have yet to be carried out, it is has an in vitro potency approximately 350x times that of morphine. [3] See also

References

  1. Killoran S, McNamara S, Kavanagh P, O'Brien J, Lakes R (May 2024). "Identification of N-pyrrolidino protonitazene in powders sold as heroin and associated with overdose clusters in Dublin and Cork, Ireland". Drug Testing and Analysis. 17 (3): 350–357. doi:10.1002/dta.3707. PMID   38769669.
  2. "N-pyrrolidino protonitazene found in brown powder sample". The Know. Australia: National Clinical Centre for Research of Emerging Drugs (NCCRED). 2024-05-18. Retrieved 2025-08-26.
  3. De Vrieze LM, Walton SE, Pottie E, Papsun D, Logan BK, Krotulski AJ, et al. (September 2024). "In vitro structure-activity relationships and forensic case series of emerging 2-benzylbenzimidazole 'nitazene' opioids". Archives of Toxicology. 98 (9): 2999–3018. Bibcode:2024ArTox..98.2999D. doi:10.1007/s00204-024-03774-7. PMC   11324687 . PMID   38877156.